Phase 2
Completed N=62
The Effect of Varenicline (Chantix) and Bupropion (Zyban) on Smoking Lapse Behavior
Smoking Lapse Behavior
Source: ClinicalTrials.gov NCT00580853 ↗
Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Mar 2017
Primary outcomePrimary: Latency to Initiate Ad-lib Smoking Session — 38.138; 39.416; 19.249 minutes
Summary
The purpose of this study is to examine how smoking cessation medications (varenicline, bupropion) affect the ability to resist smoking and also subsequent ad-lib smoking in non-treatment seeking daily smokers.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Latency to Initiate Ad-lib Smoking Session |
38.138; 39.416; 19.249 | — |
| SECONDARY Number of Cigarettes Smoked During the 60 Minute Ad-lib Period |
.713; 1.287; 2.085 | — |
Eligibility Criteria
Inclusion Criteria
- ages 18-55
- able to read and write in English
- Smokers
Exclusion Criteria
- any significant current medical or psychiatric conditions that would contraindicate smoking
- current Diagnostic and Statistical Manual IV abuse or dependence of other substances, other than nicotine dependence or alcohol abuse
- positive test result at intake appointments on urine drug screens conducted for opiates, cocaine, or benzodiazepines
- women who are pregnant or nursing
- suicidal, homicidal, or evidence of current severe mental illness
- participants prescribed any psychotropic drug in the 30 days prior to study enrollment
- blood donation within the past 6 weeks
- individuals seeking treatment for smoking cessation or have attempted to quit smoking within the past 3 months
- specific exclusions for bupropion administration not already specified, including: have taken monoamine inhibitors in the past 6 weeks; history of anorexia or bulimia; previous hypersensitivity to bupropion; history of alcohol or drug dependence in the past year; history of seizure disorder of any etiology
- known allergy to varenicline or taking H2blockers
- participation within the past 8 weeks in other studies that involve additive blood sampling and/or interventional measures that would be considered excessive in combination with the current study
Data sourced from ClinicalTrials.gov (NCT00580853). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.